Nyambura Moremi has a total of 321 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Performance characteristics of the RADI COVID-19 IgG rapid test for SARS-CoV-2 Anti-S IgG detection compared to an ELISA assay

    by Helmut Nyawale, Isabell Wagenhäuser, Julia Reusch, Juliane Mees, Salim Masoud, Omary Salim, Mathias Mlewa, Prisca Damiano, Doreen Kamori, Nyambura Moremi, et al.

    Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has posed a major global health challenge. Affordable, simple, and accurate diagnostic tools are essential for serological surveys. This study evaluated the performance of the RADI COVID-19 IgG rapid diagnostic test against the SERION ELISA and investigated factors associated with SARS-CoV-2 seropositivity.Methods: Stored serum samples from consenting participants in a region-wide serological survey conducted in three districts of Mwanza Region, Tanzania, were analyzed. Samples were tested for anti-SARS-CoV-2 IgG using the RADI COVID-19 IgG rapid test and SERION ELISA agile SARS-CoV-2 IgG as the reference method. Data were analyzed using STATA version 12.Results: A total of 710 serum samples were evaluated. Of 321 ELISA-positive samples, 312 were positive by the rapid test, yielding a sensitivity of 97.2% (95% CI: 93.1–99.3%). Among 389 ELISA-negative samples, 333 were also negative by the rapid test, giving a specificity of 85.6% (95% CI: 83.2–87.9%). Multivariable logistic regression identified a history of fever as the only independent factor associated with ELISA-confirmed SARS-CoV-2 seropositivity (adjusted odds ratio aOR: 2.111; 95% CI: 1.390–3.992; p=0.037).Conclusion: The RADI COVID-19 IgG rapid test demonstrated high sensitivity but moderate specificity compared with SERION ELISA. Its specificity may limit its suitability for SARS-CoV-2 seroepidemiological surveys in African settings, where false-positive results could lead to overestimation of seroprevalence. Further evaluations and careful considerations of test performance are necessary before its widespread use in population-based serological studies.

  • Open Access

    Strengthening systems to monitor antibiotics. An action oriented approach

    by Olafur Valsson, Elizabeth Tayler, Freddy Eric Kitutu, Jennifer Bonnah, Javiera Cornejo, Alejandro Dorado Garcia, Anahí Dreser, Aitziber Echeverria, Sabiha Y. Essack, Stanley Fenwick, et al.

    Background Antibiotics have become lynchpins of our modern systems of healthcare, animal health and agriculture. Monitoring the types and volumes of antibiotics distributed, used and discharged across these systems is critical to provide evidence for action. With limited resources, implementation of multiple tools and recommendations for antibiotic monitoring is challenging. This paper sets out principles and case study illustrations for establishing systems to monitor antibiotic supply and use in resource-constrained settings. Methods A technical working group and wider reference group drew together expertise and experience from 71 individuals representing different countries, continents and One Health domains, to establish the value of monitoring antibiotics, review tools and guidelines, share experiences and generate principles for prioritising action. This included a literature review, in person workshop, online meetings and collaborative writing between August 2024 and May 2025. Results The literature search identified two types of outputs: a) antibiotic monitoring and surveillance tools (covering data collection-oriented and residue control tools), and b) guidelines, standards, and mapping/assessment tools for monitoring antibiotics. The group identified multiple purposes for establishing a coordinated system for monitoring antibiotic use across human, animal, plant and environmental domains at country level, including ensuring access, and informing efforts to mitigate antimicrobial resistance (AMR). Tools to monitor use closer to end-user level were less standardised and often more complex. Proposed steps for establishing national antibiotic monitoring systems include starting where the greatest impact can be anticipated in a given context and alignment with other programmes. Conclusions The agricultural, population, epidemiological, cultural and economic contexts of different countries mean different starting points for establishing antibiotic monitoring. This project characterised an action-oriented prioritisation approach, targeting collection and collation of antibiotic data that have the highest likelihood of affecting change that can achieve impact. Such an approach is risk-based, prioritising monitoring of the antibiotic use that poses greatest risks as locally defined and is feasible to change; sustainable, aligning local expertise, infrastructure and technology with other country priorities; and transparent, ensuring evidence availability within the system alongside reporting ‘up and out.’ Effective national antibiotic monitoring systems require a collaborative and coordinated strategy focusing on data for action.

  • Open Access

    Genomic epidemiology reveals geographically structured co-circulation of AFR10 and AFR13 Vibrio cholerae lineages driving cholera outbreaks in Tanzania (2022–2024)

    by Ibrahim I. Mauki, Reuben Abednego, Lawrence Mapunda, Maria Ezekiely Kelly, Monica Fredrick Francis, Jackson Mushumbusi, Dennis Mrosso Kado, Feliciana Rawile, Boaz Wadugu, Hamisi Swalehe, et al.

    Cholera remains a persistent public health challenge in Tanzania, with recurrent outbreaks across multiple regions overwhelming the health systems. Despite the ongoing surveillance to control the transmission, limited genomic characterization of circulating Vibrio cholerae strains has constrained traceability of outbreak sources and transmission dynamics including virulence determinants and antimicrobial resistance profiles to guide clinical and public health interventions. We conducted a genome analysis of 144 archived isolates from 2022 to 2024 cholera outbreaks from 16 regions across Tanzania. Sequencing was performed using Oxford Nanopore platforms. Comprehensive bioinformatics analysis was applied including genome assembly, multi-locus sequence typing, resistance gene detection, virulence profiling and phylogenetic reconstruction. Of 144 isolates, sequencing confirmed 119 to be V. cholerae , of which 109 (91.6%) belonged to sequence type ST69. Phylogenetic analysis identified two distinct transmission lineages: AFR10 (formerly T10) and AFR13 (formerly T13), demonstrating marked geographic stratification. AFR10 isolates clustered predominantly around Lake Tanganyika basin, bordering the Democratic Republic of the Congo and Zambia, whereas AFR13 isolates were widely distributed across different zones of Tanzania. All isolates harboured key virulence genes ( ctxA, ctxB, tcpA ) and multiple resistance genes conferring resistance to co-trimoxazole and macrolides. The catB gene was found to be silenced in these isolates. Notably, tetracycline resistance genes ( tetA/B/C ) were absent. The qacEdelta gene was only detected in AFR13 isolates and has been linked to resistance to quaternary ammonium compounds (antiseptics and disinfectants) in Gram-negative bacteria from other studies. These findings demonstrate the co-circulation of two sublineages (AFR10 and AFR13) of the seventh pandemic El Tor lineage with distinct geographic distribution, suggesting both localized persistence and regional circulation. The observed genotypic and phenotypic susceptibility to tetracycline supports the continued use of doxycycline as a first-line therapy in adults. However, the detected macrolide resistance (an alternative treatment for children) and resistance genes associated with reduced susceptibility to antiseptics underscore the need for extensive monitoring. Strengthened national and cross-border genomic surveillance is essential for effective cholera control.

  • Population Viral Load Suppression and Associated Factors in Tanzania: Findings From 2 Sequential Tanzania HIV Impact Surveys of 2016–2017 and 2022–2023

    by Abbas Ismail, Prosper Njau, Alice Wang, Alexander Kailembo, Samwel Sumba, Baraka Revocatus, Eliezer Taluka, Mary Mayige, Tepa Nkumbula, Elias Bukundi, et al.

    Background: Antiretroviral therapy improves outcomes for people living with HIV (PLHIV) and prevents transmission through viral load suppression (VLS). To evaluate progress toward HIV epidemic control, VLS prevalences and correlates among PLHIV were analyzed from Tanzania HIV Impact Assessment Surveys (THIS), independent, cross-sectional using stratified-cluster design, conducted in 2016–2017 (S1) and 2022–2023 (S2). Methods: Participants 15 years and older provided consent, completed an interviewer-administered questionnaire, and tested for HIV using the national rapid testing algorithm. HIV-positive specimens were tested for viral load. Prevalence of population VLS (P < 0.0001) between surveys. In both surveys, women were more likely to experience VLS [S1: 1.43 (95% CI: 1.25 to 1.63), S2: 1.15 (95% CI: 1.06 to 1.24)] than men. In both surveys, PLHIV 35 years and older were more likely to experience VLS than those 15–24 years, [S1 35–49 years: 1.46 (95% CI: 1.13 to 1.90), 50 years and older: 1.69 (95% CI: 1.28 to 2.23), and S2 35–49 years: 1.31 (95% CI: 1.06 to 1.62), 50 years and older: 1.42 (95% CI: 1.15 to 1.76)]. Conclusion: Tanzania has made progress toward HIV epidemic control, as evidenced by the significant increase in VLS prevalence in 6 years. Targeted sex–age strategies are essential for HIV epidemic control.

  • Open Access

    Detection of Coxsackievirus A24v during an acute haemorrhagic conjunctivitis outbreak in Dar es Salaam, Tanzania, January-February 2024

    by Lawrence A. Mapunda, Peter van Heusden, Robert Baluhya, Olympia G. Machange, Ambele Mwafulango, Monica Fredrick Francis, Aziz Ituka, Omega Machange, Adela Kisanga, Edna E. Mgimba, et al.

    Background: In January 2024, an outbreak of acute viral conjunctivitis was declared in Dar es Salaam, Tanzania, following initial case clusters reported in December 2023 and continuing through February. Patients presented with red, itchy, and burning eyes, eyelid swelling, photophobia, and eye discharges. As the responsible pathogen had not been laboratory-identified, this study aimed to detect and characterize potential viral agents of the outbreak through an urgent outbreak response investigation. Methods: Conjunctival swabs were collected from 25 suspected cases using a convenience sampling approach. Bacterial culture was performed on MacConkey and blood agar. Viral detection used a multiplex real-time RT-PCR targeting adenovirus, metapneumovirus, enterovirus (EV), and parainfluenza virus. All enterovirus-positive samples with a Ct value <30 (four samples) were selected for genomic sequencing on an Illumina MiSeq platform. Maximum-likelihood phylogenetic analysis was conducted with IQ-TREE. Results: Nine of 25 samples (36%) were positive for enterovirus (EV) by real-time reverse transcription PCR. Genomic sequencing of the four eligible samples (Ct < 30) detected Coxsackievirus A24 variant (CVA24v) in two of four sequenced samples. Phylogenetic analysis showed that the Tanzanian outbreak sequences formed a clade with CVA24v strains from a concurrent 2024 outbreak in France/Mayotte and were closely related to recent sequences from East Africa and South America. Bacterial culture yielded no significant pathogens. Conclusion: We detected enterovirus (EV) during an outbreak of acute hemorrhagic conjunctivitis in Tanzania. Of nine EV-positive samples, CVA24v genomes were reconstructed from genomic sequencing in two samples, with phylogenetic analysis placing Tanzania sequencences within a clade with sequences from France (Mayotte), Mexico, Brazil, and Uganda strains consistent with regional circulation. Given that sequencing was performed on only two samples, a causal role for CVA24v in this outbreak cannot be definitively established; however, these findings provide the first genomic evidence of CVA24v circulation in Tanzania and demonstrate the value of rapid genomic epidemiology for outbreak pathogen detection in resource-limited settings.

  • Open Access

    The Quality Management System in Medical Laboratories: Seventeen Years of Strengthening Laboratory Management Towards ISO 15189 Accreditation in Tanzania

    by Peter Richard Torokaa, Regnald Julius, Nyambura Moremi, Charles Massambu, Mtebe Majigo, Agricola Joachim, Alice Kyalo, Maria E. Kelly, Jacob Lusekelo

    Background Recent advances in development and changes in laboratory technology seen in modern medicine have increased the demand on timely, accurate, reliable, and reproducible laboratory results. In public health settings, the laboratory plays a key role in disease surveillance for early detection and confirmation of disease outbreaks. We aimed to describe and document the 15189 accreditation in Tanzania. Methods We conducted a cross-sectional study involving databases for medical laboratories in the Ministry of Health and African Society for Laboratory Medicine (ASLM). All laboratories which participated in quality management system in Tanzania were included in the study from national to health centre levels. Results Out of 157 laboratories implementing QMS from 2007 to 2024, a total of 81 (51.6%) laboratories were accredited. Secondary laboratory level had high number of enrolments into QMS program 117 (74.5%) followed by tertiary laboratories 26 (16.6%). The proportion of accredited laboratories at tertiary level was (73.1%) (p < 0.033) which was significantly higher compared to other levels. There was significantly higher proportion of laboratories accredited through direct laboratory accreditation process 25/28, (89.3%), compared with SLMTA program 59/129 (44.4%) (p < 0.001 ). There was a significant increase of accredited laboratories among SLMTA program from 1/76 (1.3%) in 2017 to 56/157 (35.7%) in 2024, ( p = 0.027) compared to direct laboratory accreditation approach. Conclusions Laboratory accreditation is a hallmark of quality management system implementation which can be achieved either through direct laboratory accreditation approach or the SLMTA program. The seventeen years of experience in implementing QMS indicates that the SLMTA program is more efficient, effectiveness and user-friendly than the direct laboratory accreditation approach.

  • Open Access

    Strengthening laboratory management towards accreditation in Tanzania: The 13 years of remarkable revolutions in laboratory quality management system

    by Peter Richard Torokaa, Charles Massambu, Jacob Lusekelo, Regnald Julius, Alex Sifael Magesa, Mtebe Majigo, Agricola Joachim, Maria Ezekiely Kelly, Alice Kyalo, Nyambura Moremi

    Introduction: The increase in demand of laboratory services and recent advancements in laboratory technologies underscore the importance of quality laboratory services in delivering accurate, reliable, and timely test results. As a strategy to ensure quality laboratory services in the country, Tanzania started to implement Strengthening Laboratory Management Towards Accreditation (SLMTA) program in 2010. We describe the revolutions made in laboratory quality management system across the 13 years of SLMTA implementation highlighting the impact and achievements attained following the modification of the generic SLMTA approach. Methodology: We evaluated, described and summarized the 13 years of SLMTA implementation in Tanzania and the quality performance of medical laboratories enrolled into the program. The quality performance was evaluated based on the increase in number of SLMTA laboratories accredited under ISO 15189 by comparing the laboratories enrolled during the generic versus modified SLMTA program. Results: Out of 138 SLMTA laboratories assessed by 2023 using the SLIPTA checklist, 81 (58.7%) scored 3 stars and above were enrolled in the accreditation process. Of the 81 enrolled laboratories, 50 (61.7%) achieved ISO 15189 accreditation status by 2023. There was a significant increase in number of accredited laboratories during the five years (2018–2023) of modified SLMTA compared to the eight years (2010–2018) of generic SLMTA (47/64 vs. 3/17, p = 0.021). In the context of level of healthcare delivery, most of the accredited laboratories (n = 47/50, 94%), belonged to the district level and above. Conclusion: To the best of our knowledge, this is the first report of the modified SLMTA approach with remarkable results. The modified SLMTA program significantly improved the status and number of accredited laboratories in Tanzania. While the attained milestone demonstrates the SLMTA program’s effectiveness in strengthening quality of laboratory services, the significant achievements underscore the essence of monitoring, evaluation and learning of the implemented programs, and most importantly the need for strategies that contextualize and tailor the program for sustainability.


  • Open Access

    Change in HIV Incidence, Prevalence and Population Viremia in Tanzania: Findings from Tanzania HIV Impact Surveys in 2016–2017 and 2022–2023

    by Prosper Faustine Njau, Sarah Porter, Abbas Kihame Ismail, Alice Wang, Alexander Kailembo, George S. Mgomella, Damian Damian, Optatus Malewo, Mohamed F. Jalloh, Faki H. Faki, et al.

    Background: Tanzania has over 1.5 million people living with HIV. Understanding changes in its HIV epidemic is critical to informing interventions and policies. We aim to describe the state of Tanzania’s HIV epidemic and progress towards epidemic control by evaluating changes in population-level HIV prevalence, HIV incidence, and viremia between 2016–2017 and 2022–2023. Methods: Sequential Tanzania HIV Impact Surveys (THIS) 2016–2017 and 2022–2023 were nationally-representative, cross-sectional household-based surveys with a stratified, two-stage cluster design. Participants aged ≥15 years provided information on HIV testing and treatment histories and blood samples for HIV serology. HIV incidence was estimated using a laboratory-based algorithm (HIV-1 Limiting Antigen (Lag) avidity, viral load (VL), and antiretroviral (ARV) detection). We calculated weighted estimates of population-level HIV prevalence, HIV incidence, and viremia and compared them between surveys. Arithmetic differences and incidence rate ratios were used to assess change. Modified Poisson regression models were used to estimate adjusted prevalence ratios (aPR) for correlates of HIV prevalence and viremia. Findings: Among participants aged ≥15 years with biomarker data (n=31,579 in 2016–2017; n=33,663 in 2022–2023), 1,831 and 1,850 were living with HIV, respectively. HIV prevalence remained stable at 4.9% [95% CI: 4.5–5.2] in 2016–2017 and 4.4% [4.1–4.7] in 2022–2023. Annual HIV incidence did not significantly change (0.24% [0.15–0.34] vs. 0.18% [0.09–0.26]). Population viremia declined significantly from 2.8% [2.6–3.1] to 1.7% [1.5–1.8], with a 41% reduction between surveys (aPR: 0.59 [0.52–0.67]). Higher prevalence and viremia were observed among women and adults aged ≥25 years. Interpretation: Between 2016–2017 and 2022–2023, HIV prevalence and incidence remained stable in Tanzania, while population viremia declined substantially, indicating progress towards HIV epidemic control. Continued efforts and targeted interventions are needed to reduce viremia among women and older age groups.

  • Open Access

    Antibiotic surveillance: an action-oriented integrated approach

    by Olafur Valsson, Elizabeth Tayler, Freddy Eric Kitutu, Jennifer Bonnah, Javiera Cornejo, Alejandro Dorado Garcia, Anahí Dreser, Aitziber Echeverria, Sabiha Y. Essack, Stanley Fenwick, et al.

    Background Antibiotics have become lynchpins of our modern systems of healthcare, animal health and agriculture. Monitoring the types and volumes of antibiotics distributed, used and discharged across these systems is critical to provide evidence for action. With limited resources, implementation of multiple tools and recommendations for antibiotic monitoring is challenging. This paper sets out the principles and case study illustrations for establishing antibiotic surveillance in resource-constrained settings. Methods A technical working group drew together expertise and experience from around the world and across One Health domains to establish the value of antibiotic surveillance across sectors, review tools and guidelines, share experiences and generate principles for prioritisation of surveillance activity. This included a literature review, in person workshop, online meetings and collaborative writing between August 2024 and May 2025. Results The working group identified multiple purposes for establishing a coordinated antibiotic surveillance within countries, to inform efforts to mitigate antimicrobial resistance (AMR) mitigation efforts and beyond. Tools showed increasing complexity towards the end user level, corresponding with decreasing standardisation in approach. Proposed steps for establishing national antibiotic surveillance included starting where the greatest impact can be anticipated in a given context and alignment with other programmes. Conclusions Countries vary in their agricultural, population, epidemiological, cultural and economic contexts and require different starting points for establishing antibiotic surveillance. This project characterised an action-oriented prioritisation approach, targeting collection and collation of antibiotic data that have the highest likelihood of affecting change that can achieve impact. Such an approach is risk-based, prioritising surveillance of antibiotic use that poses greatest risks as locally defined and is feasible to change; sustainable, aligning local expertise, infrastructure and technology with other country priorities; and transparent, ensuring evidence availability within the system alongside reporting ‘up and out.’ Achieving effective antibiotic surveillance requires a collaborative and coordinated strategy focusing on data for action.


  • Open Access

    Genomic Insights into Marburg Virus Strains from 2023 and 2025 Outbreaks in Kagera, Tanzania

    by Lawrence A. Mapunda, Medard Beyanga, Nyambura Moremi, Jean N. Hakizimana, Doreen Kamori, Alfred Chacha, Edna Mgimba, Dennis Mrosso, Ambele E. Mwafulango, Jackson Mushumbusi, et al.

    Marburg Virus from 2023 and 2025, Tanzania